CYTOMEL® 17 PATIENT COUNSELING INFORMATION

(liothyronine sodium)

17 PATIENT COUNSELING INFORMATION

Dosing and Administration

Instruct patients that CYTOMEL should only be taken as directed by their healthcare provider.
Instruct patients to notify their healthcare provider should they become pregnant or breastfeeding or are thinking of becoming pregnant, while taking CYTOMEL.

Important Information

Inform patients that the liothyronine in CYTOMEL is intended to replace a hormone that is normally produced by the thyroid gland. Generally replacement therapy is to be taken for life.
Inform patients that CYTOMEL should not be used as a primary or adjunctive therapy in a weight control program.
Instruct patients to notify their healthcare provider if they are taking any other medications, including prescription and over-the-counter preparations.
Instruct patients to notify their healthcare provider of any other medical conditions, particularly heart disease, diabetes, clotting disorders, and adrenal or pituitary gland problems, as the dose of medications used to control these other conditions may need to be adjusted while taking CYTOMEL. If patents are taking anticoagulants (blood thinners), their clotting status should be checked frequently.
Instruct patients to notify their physician or dentist if they are taking CYTOMEL prior to any surgery.

Adverse Reactions

Instruct patients to notify their healthcare provider if they experience any of the following symptoms: rapid or irregular heartbeat, chest pain, shortness of breath, leg cramps, headache, nervousness, irritability, sleeplessness, tremors, change in appetite, weight gain or loss, vomiting, diarrhea, excessive sweating, heat intolerance, fever, changes in menstrual periods, hives or skin rash, or any other unusual medical event [see Adverse Reactions (6)].
Inform patients that partial hair loss may occur rarely during the first few months of CYTOMEL therapy; this is usually temporary [see Adverse Reactions (6)].

Find CYTOMEL® medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

CYTOMEL® Quick Finder

Medication Guide

Health Professional Information

17 PATIENT COUNSELING INFORMATION

Dosing and Administration

Instruct patients that CYTOMEL should only be taken as directed by their healthcare provider.
Instruct patients to notify their healthcare provider should they become pregnant or breastfeeding or are thinking of becoming pregnant, while taking CYTOMEL.

Important Information

Inform patients that the liothyronine in CYTOMEL is intended to replace a hormone that is normally produced by the thyroid gland. Generally replacement therapy is to be taken for life.
Inform patients that CYTOMEL should not be used as a primary or adjunctive therapy in a weight control program.
Instruct patients to notify their healthcare provider if they are taking any other medications, including prescription and over-the-counter preparations.
Instruct patients to notify their healthcare provider of any other medical conditions, particularly heart disease, diabetes, clotting disorders, and adrenal or pituitary gland problems, as the dose of medications used to control these other conditions may need to be adjusted while taking CYTOMEL. If patents are taking anticoagulants (blood thinners), their clotting status should be checked frequently.
Instruct patients to notify their physician or dentist if they are taking CYTOMEL prior to any surgery.

Adverse Reactions

Instruct patients to notify their healthcare provider if they experience any of the following symptoms: rapid or irregular heartbeat, chest pain, shortness of breath, leg cramps, headache, nervousness, irritability, sleeplessness, tremors, change in appetite, weight gain or loss, vomiting, diarrhea, excessive sweating, heat intolerance, fever, changes in menstrual periods, hives or skin rash, or any other unusual medical event [see Adverse Reactions (6)].
Inform patients that partial hair loss may occur rarely during the first few months of CYTOMEL therapy; this is usually temporary [see Adverse Reactions (6)].

Prescribing Information

Download Prescribing Information

Health Professional Information

17 PATIENT COUNSELING INFORMATION

Dosing and Administration

Instruct patients that CYTOMEL should only be taken as directed by their healthcare provider.
Instruct patients to notify their healthcare provider should they become pregnant or breastfeeding or are thinking of becoming pregnant, while taking CYTOMEL.

Important Information

Inform patients that the liothyronine in CYTOMEL is intended to replace a hormone that is normally produced by the thyroid gland. Generally replacement therapy is to be taken for life.
Inform patients that CYTOMEL should not be used as a primary or adjunctive therapy in a weight control program.
Instruct patients to notify their healthcare provider if they are taking any other medications, including prescription and over-the-counter preparations.
Instruct patients to notify their healthcare provider of any other medical conditions, particularly heart disease, diabetes, clotting disorders, and adrenal or pituitary gland problems, as the dose of medications used to control these other conditions may need to be adjusted while taking CYTOMEL. If patents are taking anticoagulants (blood thinners), their clotting status should be checked frequently.
Instruct patients to notify their physician or dentist if they are taking CYTOMEL prior to any surgery.

Adverse Reactions

Instruct patients to notify their healthcare provider if they experience any of the following symptoms: rapid or irregular heartbeat, chest pain, shortness of breath, leg cramps, headache, nervousness, irritability, sleeplessness, tremors, change in appetite, weight gain or loss, vomiting, diarrhea, excessive sweating, heat intolerance, fever, changes in menstrual periods, hives or skin rash, or any other unusual medical event [see Adverse Reactions (6)].
Inform patients that partial hair loss may occur rarely during the first few months of CYTOMEL therapy; this is usually temporary [see Adverse Reactions (6)].

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985^*

*Contact Medical Information.9AM-5PM ET Monday to Friday; excluding holidays.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.